Articles

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma

University of Saskatchewan, SK, Canada
University of Calgary, AB, Canada
Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada
University of Calgary, AB, Canada
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada
Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada
University of Toronto, ON, Canada
Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada
BC Cancer Agency, Vancouver, BC, Canada
University of Calgary, AB, Canada
Vol. 103 No. 2 (2018): February, 2018 https://doi.org/10.3324/haematol.2017.179309